Goleta-based Deckers on July 30 reported a loss of $47.3 million in its fiscal first quarter and a loss of $1.43 on a per-share basis. Despite the per-share loss, the results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.51 per share. Deckers Read More →
Thousand Oaks-based Amgen Inc. posted second-quarter profit that topped analysts’ estimates, driven by higher sales and lower operating expenses. The biotech also raised its revenue and earnings forecast for the year. Profit excluding one-time items rose to $2.57 a share, while analysts had predicted $2.43 on average. Revenue increased 3.7 percent to $5.37 billion, the Read More →
Venoco has asked the city of Goleta for emergency authority to move two truckloads per day of oil from its Ellwood facility to Santa Maria for the next 17 days. Venoco said it was making the request so that lines and other facilities could be cleared in order to complete mandatory inspections. Venoco said it Read More →
The Pacific Coast Business Times is pleased to announce our 2015 class of Spirit of Small Business award winners. The annual special section, now in its 13th year, celebrates small-business ownership and entrepreneurship in the Tri-Counties. The report published with the July 24 print edition of the Business Times. The honorees will be celebrated Read More →
UC Santa Barbara’s Institute for Energy Efficiency will play a lead role in a $110 million federal program to develop new electronic products using the next generation of chip technology. UCSB will become the west coast hub for the newly formed American Institute for Manufacturing of Photonics (AIM), teaming with lead institution State University of Read More →
The Food and Drug Administration approved Amgen’s Kyprolis for second-line treatments of multiple-myeloma on Friday. Thousand Oaks-based Amgen’s new treatment for multiple-myeloma could pay off big for the company now that the treatment can be accessed by more patients in the second line of treatments. Kyprolis was approved for third-line treatments in 2012. The FDA’s Read More →
Thousand Oaks-based Amgen announced Thursday that it submitted data comparing its new multiple-myeloma drug against a rival to the Food and Drug Administration. Kyprolis is Amgen’s new treatment for multiple-myeloma, which is a form of blood cancer that forms in plasma cells and typically grows in bone marrow. The drug was approved for third-line treatments Read More →
